<DOC>
	<DOCNO>NCT02653976</DOCNO>
	<brief_summary>This study phase 2 multinational , multicenter , single-arm , open-label , non-randomized study evaluate efficacy safety SP-02L monotherapy relapse refractory patient peripheral T-cell lymphoma .</brief_summary>
	<brief_title>A Phase 2 Study SP-02L Patients With Relapsed Refractory Peripheral T-cell Lymphoma ( PTCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>Patients Japanese , Korean , Taiwanese , Chinese ethnic background country/region Patients age â‰¥20 year date inform consent Patients histologically confirm diagnosis one following : Peripheral Tcell lymphoma otherwise specify ( PTCLNOS ) Angioimmunoblastic Tcell Lymphoma ( AITL ) Anaplastic large cell lymphoma ( ALCL ) , ( ALKpositive/negative ) Relapsed refractory patient treatment history least one regimen antitumor agent disease Have least 1 measurable lesion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Patients life expectancy least 3 month determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>